Merck and BioMed X expand collaboration to immunology research

On February 15, 2019, Posted by , In News, By , , With Comments Off on Merck and BioMed X expand collaboration to immunology research

Heidelberg, Germany, February 14th, 2019 – BioMed X announced today to add a further research program to the collaboration with Merck. In accordance with the provisions of the existing contract, a new crowdsourcing project will be launched in the field of autoimmune diseases. BioMed X and Merck started their partnership…

Miltenyi Biotec joins EMBL’s Corporate Partnership Programme

On January 18, 2019, Posted by , In News, By , , With Comments Off on Miltenyi Biotec joins EMBL’s Corporate Partnership Programme

Joining forces to advance training in biomedical research and therapy EMBL and Miltenyi Biotec, a global provider of products and services that advance biomedical research and cellular therapy from basic and translational research to clinical application, have teamed up in the EMBL Advanced Training Centre Corporate Partnership Programme to advance research…

AbbVie: towards innovative therapies with “Alfons”

On January 15, 2019, Posted by , In News, By , , With Comments Off on AbbVie: towards innovative therapies with “Alfons”

What does the future of research actually look like? Alfons” gives an answer to this question. What sounds like a first name that has gone out of fashion stands for the finest in high technology. “Automated Liquid Formulation Screening” is a real innovation: Using the data generated with this system,…

Sanofi joins Open Targets

On October 31, 2018, Posted by , In News, By , , With Comments Off on Sanofi joins Open Targets

Sanofi has joined Open Targets, the public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. Public-private collaboration Open Targets announced today that Sanofi has joined its pioneering public-private collaboration to transform drug discovery by improving the success rate for developing new medicines. Sanofi’s expertise…

EMBL/Sanofi: More effective insulin thanks to first 3D image

On October 29, 2018, Posted by , In News, By , , With Comments Off on EMBL/Sanofi: More effective insulin thanks to first 3D image

An international collaboration has revealed how to make therapeutic insulins more effective than they currently are. The findings – published in Nature Communications on 24 October – will help to improve treatments for diabetes, a disease that impacts the lives of millions of people worldwide. Insulin receptor structural biology. IMAGE:…

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

On October 15, 2018, Posted by , In News, By , , With Comments Off on Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

Ready-to-use kits determine genomic characteristics of solid tumours Optimized workflow to generate results in house Software analysis allows correlation to AVENIO ctDNA NGS kits Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO…

Is it possible to pitch the full potential of discoveries without spilling the secret sauce?

On October 4, 2018, Posted by , In Press Releases, By , , With Comments Off on Is it possible to pitch the full potential of discoveries without spilling the secret sauce?

Heidelberg, 04.10.2018 On Tuesday October 2, Guenter Huhle, Head of JLABS EMEA, Johnson & Johnson Innovation shared key insights on the art of pitching in front of a packed audience of researchers, entrepreneurs and professionals mainly from the Heidelberg area.   Panel discussion: Maciek Drozdz (Principal of Venture Investments for…

VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings

On September 24, 2018, Posted by , In News, By , With Comments Off on VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings

CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian countries, ex-Japan VAXIMM to receive potential development and commercial milestone payments plus royalties on sales CMS to make an equity investment in VAXIMM Basel (Switzerland) and Mannheim (Germany), September 20, 2018 –…

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager – based Immunotherapeutics for Multiple Cancer Targets

On August 29, 2018, Posted by , In News, By , , With Comments Off on Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager – based Immunotherapeutics for Multiple Cancer Targets

Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales. Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to…

PEPperPRINT granted new US patent

On July 18, 2018, Posted by , In News, By , With Comments Off on PEPperPRINT granted new US patent

PEPperPRINT latest patent covers a novel method for producing high-density peptide microarrays PEPperPRINT is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,925,509 covering a method for the generation of high-density peptide microarrays by means of a combinatorial laser induced forward…